TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07377045: Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

Sponsor: Oncomatryx Biopharma S.L. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 69 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT07377045 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07377045 Rescue Dossier →